Inuzuka Ryo, Nii Masaki, Inai Kei, Shimada Eriko, Shinohara Tokuko, Kogiso Tomomi, Ono Hiroshi, Otsuki Shin-Ichi, Kurita Yoshihiko, Takeda Atsuhito, Hirono Keiichi, Takei Kota, Yasukohchi Satoshi, Yoshikawa Tadahiro, Furutani Yoshiyuki, Shinozaki Tomohiro, Matsuyama Yutaka, Senzaki Hideaki, Tokushige Katsutoshi, Nakanishi Toshio
Department of Pediatrics, University of Tokyo, Tokyo, Japan.
Pediatric Cardiology, Shizuoka Children's Hospital, Shizuoka, Japan.
Heart. 2023 Jan 27;109(4):276-282. doi: 10.1136/heartjnl-2022-320940.
Fontan-associated liver disease (FALD) is widely recognised as a common complication in patients long after the Fontan operation. However, data on the predictors of FALD that can guide its screening and management are lacking. The present study aimed to identify the predictors of liver cirrhosis (LC) and hepatocellular carcinoma (HCC) in post-Fontan patients.
This was a multi-institutional retrospective cohort study. Clinical data of all perioperative survivors of Fontan operation before 2011 who underwent postoperative catheterisation were collected through a retrospective chart review.
A total of 1117 patients (538 women, 48.2%) underwent their first Fontan operation at a median age of 3.4 years. Postoperative cardiac catheterisation was conducted at a median of 1.0 year. During a median follow-up period of 10.3 years, 67 patients (6.0%) died; 181 (16.2%) were diagnosed with liver fibrosis, 67 (6.0%) with LC, 54 (4.8%) with focal nodular hyperplasia and 7 (0.6%) with HCC. On multivariable analysis, high central venous pressure (CVP) (HR, 1.28 (95% CI 1.01 to 1.63) per 3 mm Hg; p=0.042) and severe atrioventricular valve regurgitation (HR, 6.02 (95% CI 1.53 to 23.77); p=0.010) at the postoperative catheterisation were identified as independent predictors of LC/HCC.
Patients with high CVP and/or severe atrioventricular valve regurgitation approximately 1 year after the Fontan operation are at increased risk of developing advanced liver disease in the long term. Whether therapeutic interventions to reduce CVP and atrioventricular valve regurgitation decrease the incidence of advanced liver disease requires further elucidation.
Fontan相关肝病(FALD)被广泛认为是Fontan手术多年后患者的常见并发症。然而,缺乏可指导其筛查和管理的FALD预测因素的数据。本研究旨在确定Fontan术后患者肝硬化(LC)和肝细胞癌(HCC)的预测因素。
这是一项多机构回顾性队列研究。通过回顾性病历审查收集了2011年前接受Fontan手术且术后进行导管插入术的所有围手术期幸存者的临床数据。
共有1117例患者(538例女性,48.2%)在3.4岁的中位年龄接受了首次Fontan手术。术后导管插入术的中位时间为1.0年。在10.3年的中位随访期内,67例患者(6.0%)死亡;181例(16.2%)被诊断为肝纤维化,67例(6.0%)为LC,54例(4.8%)为局灶性结节性增生,7例(0.6%)为HCC。多变量分析显示,术后导管插入术时的高中心静脉压(CVP)(每3 mmHg的风险比[HR]为1.28[95%置信区间为1.01至1.63];p=0.042)和严重房室瓣反流(HR为6.02[95%置信区间为1.53至23.77];p=0.010)被确定为LC/HCC的独立预测因素。
Fontan手术后约1年出现高CVP和/或严重房室瓣反流的患者,长期发生晚期肝病的风险增加。降低CVP和房室瓣反流的治疗干预措施是否能降低晚期肝病的发生率,需要进一步阐明。